GRAIL to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
GRAIL (NASDAQ:GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
GRAIL (NASDAQ:GRAL), a healthcare company focused on early cancer detection, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will deliver their presentation on Tuesday, September 9 at 1:50 p.m. ET.
Investors can access both the live presentation and replay through GRAIL's investor relations website at investors.grail.com. The webcast recording will remain available for a minimum of 30 days following the event.
Details
News Market Reaction – GRAL
On Aug 27, the first trading day after this news, GRAL closed 1.29% below the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-morgan-stanley-23rd-annual-global-healthcare-conference-302538075.html
SOURCE GRAIL, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.